8-K: Guardant Health Q2 2026 Results: Revenue Surges 44%, Guidance Raised

Guardant Health reported a 44% year-over-year revenue increase to $335.0 million for the second quarter of 2026, driven by strong performance in Oncology and Screening, leading to an upward revision of full-year revenue guidance.

Summary

• Guardant Health announced second quarter 2026 financial results, with total revenue reaching $335.0 million, a 44% increase compared to the same period in 2025.
• Oncology revenue grew by 38% to $219.1 million, with a 63% increase in test volume to approximately 104,000 tests.
• Screening revenue saw substantial growth, increasing over 250% to $52.9 million, with Shield screening test volume rising to approximately 66,000 tests from 16,000 in the prior year.
• Biopharma & Data revenue increased by 9% to $60.9 million.
• The company raised its full-year 2026 revenue guidance to a range of $1.34 to $1.36 billion, representing 36% to 38% growth.
• Non-GAAP gross margin was 67% for the quarter, up from 66% in the prior year.
• Net loss for the quarter was $120.1 million, or $0.90 per share, compared to a net loss of $99.9 million, or $0.80 per share, in the prior year.
• Non-GAAP net loss was $56.2 million, or $0.42 per share, an improvement from $0.44 per share in the prior year.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with significant revenue growth, raised guidance, and key regulatory and market access wins, despite an increase in net loss.

Positives

• Total revenue increased by 44% year-over-year to $335.0 million.
• Oncology revenue grew 38% to $219.1 million, with a significant 63% increase in test volume.
• Screening revenue experienced over 250% growth, reaching $52.9 million, driven by a substantial increase in Shield test volume.
• Full-year 2026 revenue guidance was raised to $1.34-$1.36 billion (36%-38% growth), up from previous guidance of $1.30-$1.32 billion.
• Non-GAAP gross margin improved to 67% from 66% year-over-year.
• Received FDA approval for Guardant360 Liquid CDx.
• Shield test included in the American Cancer Society's updated colorectal cancer screening guidelines.
• Obtained Shield coverage from UnitedHealth Group.

Negatives

• Net loss increased to $120.1 million ($0.90 per share) from $99.9 million ($0.80 per share) in the prior year's quarter.
• Operating expenses increased to $348.1 million from $257.3 million year-over-year, primarily due to commercial infrastructure expansion and marketing.
• Non-GAAP operating expenses also increased significantly.
• Free cash flow for the quarter was $(69.5) million, a slight increase in burn compared to $(65.9) million in the prior year.
• Full-year free cash flow burn is now expected to be $195-$205 million, an increase from the previous outlook of $185-$195 million.

Risks

• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, including factors discussed in the company's Form 10-K and other SEC filings.
• Increased operating expenses related to commercial infrastructure expansion and marketing activities could impact profitability.
• The company's ability to continue scaling its Shield volume and securing broader coverage and adoption in colorectal cancer screening.

Future Outlook

Guardant Health raised its full-year 2026 revenue guidance to $1.34 to $1.36 billion (36%-38% growth). Oncology revenue is now expected to grow approximately 30%, with oncology volume growing to approximately 50%. Screening revenue is projected to be $218-$230 million. Full-year non-GAAP gross margin is expected to be 64%-65%. Total non-GAAP operating expenses are now expected to be $1.08-$1.10 billion. Full-year free cash flow burn is projected to be $195-$205 million.

Management Comments

• "Our second-quarter performance reflected broad-based momentum across the Guardant portfolio, with revenue increasing 44% year over year, fueled by strong oncology volume, with acceleration across every product."
• "The landmark FDA approval of Guardant360 Liquid CDx further strengthens our portfolio and positions us to drive sustained growth in the years ahead."
• "Our team delivered another quarter of exceptional growth for Shield, and we are excited about several important milestones that reinforce its expanding role in colorectal cancer screening."
• "The inclusion of the Shield blood test in the American Cancer Society's screening guidelines, together with UnitedHealth Group's broad coverage decision, represents powerful validation of Shield's clinical utility and its potential to improve access to screening."

Industry Context

StockSavvy.ai notes that Guardant Health's strong Q2 performance and raised guidance align with the growing trend in precision oncology and the increasing adoption of liquid biopsy for cancer detection and management. The FDA approvals and inclusion in screening guidelines highlight the company's progress in validating its technology and expanding market access, positioning it favorably within the competitive landscape of cancer diagnostics.

Comparison to Industry Standards

• The 44% year-over-year revenue growth in Q2 2026 significantly outpaces the typical growth rates seen in the broader healthcare diagnostics sector.
• The substantial increase in Shield screening test volume (over 250%) demonstrates rapid market penetration, which is a key benchmark for disruptive screening technologies.
• The inclusion of Shield in the American Cancer Society guidelines and coverage by a major insurer like UnitedHealth Group are critical milestones that set a new standard for blood-based colorectal cancer screening, potentially influencing other companies in the field.

Stakeholder Impact

• Shareholders: Positive impact from raised revenue guidance and strong growth, potentially leading to increased valuation, though net loss widened.
• Patients: Improved access to advanced cancer diagnostics and screening through FDA approvals and new coverage.
• Healthcare Providers: Enhanced tools for cancer detection, monitoring, and treatment selection.
• Insurers: Validation of blood-based screening technologies, potentially leading to broader coverage decisions.

Next Steps

• Continue to drive growth in Oncology and Screening segments.
• Leverage FDA approvals for Guardant360 Liquid CDx and Guardant360 CDx.
• Expand Shield coverage and adoption in colorectal cancer screening.
• Invest in laboratory capacity to support Shield volume growth.
• Host conference call on July 30, 2026, to discuss Q2 results.

Key Dates

Recommendation

The company demonstrated robust top-line growth, significantly exceeded expectations in key areas like screening volume, and raised its full-year guidance. Key regulatory approvals and market access wins (FDA, ACS, UnitedHealth Group) provide strong validation and de-risk future adoption. While net losses persist and free cash flow burn increased, the accelerated growth trajectory and strategic advancements strongly outweigh these concerns for a growth-oriented investor.

Keywords

precision oncology, liquid biopsy, cancer screening, Guardant360, Shield, colorectal cancer, companion diagnostic, FDA approval